Key result
Warfarin significantly reduced the risk of stroke compared to placebo in patients with non-rheumatic atrial fibrillation (OR 0.30; 95% CI 0.19-0.48), with a moderate increase in major bleeding.
Why the study?
Do anticoagulants or antiplatelet therapy reduce stroke in adults with non-rheumatic atrial fibrillation?
Population
Adults with non-postoperative, non-rheumatic atrial fibrillation and flutter (14 RCTs)
Comparison
Anticoagulants or antiplatelet therapy vs Placebo or active comparator (warfarin vs aspirin)
Design
Meta-analysis
Authors
Loading...
Supports warfarin for stroke prevention in non-rheumatic AF despite bleeding risk; confirms efficacy versus placebo across RCTs.
Meta-Analysis
Do anticoagulants or antiplatelet therapy reduce stroke in adults with non-rheumatic atrial fibrillation?
Odds Ratio: 0.3 (95% CI 0.19–0.48)
Warfarin significantly reduces the risk of stroke in patients with non-rheumatic atrial fibrillation compared to placebo and aspirin, though with an increased risk of major hemorrhage.
Segal et al. (2006) conducted a meta-analysis in non-rheumatic atrial fibrillation and flutter. Warfarin vs. Placebo was evaluated on stroke (OR 0.30, 95% CI 0.19-0.48). Warfarin significantly reduced the risk of stroke compared to placebo in patients with non-rheumatic atrial fibrillation (OR 0.30; 95% CI 0.19-0.48), with a moderate increase in major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: